Current status of the therapy of advanced renal carcinoma
โ Scribed by William J. Hrushesky; Dr. Gerald P. Murphy
- Publisher
- John Wiley and Sons
- Year
- 1977
- Tongue
- English
- Weight
- 704 KB
- Volume
- 9
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
A preclinical murine renal tumor model system is available for evaluation of the effectiveness of therapeutic agents. Clinical review reveals that objective response rates to hormonal agents reported since 1971 have been substantially lower than those reported prior to 1971. Many chemotherapeutic agents have not been adequately evaluated clinically or with the experimental model. Vinblastine to date may be the most active single agent with a 25% objective response rate. At the present time, it is uncertain whether combination chemotherapy or hormonal chemotherapy add to response rates obtained with single agents. There is some evidence that immunotherapy may be of some adjuvant benefit and, thus, may provide an additional avenue of investigation.
๐ SIMILAR VOLUMES
## Abstract About 5โ10 years ago it became popular to say that we understood the genetic and molecular basis for sickle cell anemia better than for any other disease and yet had no effective treatment. It was correctly pointed out that very little money was being spent at that time on sickle cell r
## BACKGROUND. The grading of renal cell carcinoma (RCC) has a long history. Currently, there are several grading systems in use throughout the world. There is no consensus regarding which grading system is optimal. ## METHODS. A review of the patient outcome cutpoints of several RCC grading sy
E arly detection of hepatocellular carcinoma (HCC) is important, since the most effective treatment for HCC is surgical resection or local ablation therapy when the tumor is small. Fortunately, recent advances in liver imaging techniques have facilitated the detection of small HCCs. ## Recent progr